193 related articles for article (PubMed ID: 33653693)
1. CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors.
Germano G; Lu S; Rospo G; Lamba S; Rousseau B; Fanelli S; Stenech D; Le DT; Hays J; Totaro MG; Amodio V; Chilà R; Mondino A; Diaz LA; Di Nicolantonio F; Bardelli A
Cancer Discov; 2021 Jul; 11(7):1844-1859. PubMed ID: 33653693
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.
Koelzer VH; Baker K; Kassahn D; Baumhoer D; Zlobec I
J Clin Pathol; 2012 Nov; 65(11):996-1002. PubMed ID: 22859396
[TBL] [Abstract][Full Text] [Related]
3. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice.
Christianson SW; Greiner DL; Hesselton RA; Leif JH; Wagar EJ; Schweitzer IB; Rajan TV; Gott B; Roopenian DC; Shultz LD
J Immunol; 1997 Apr; 158(8):3578-86. PubMed ID: 9103418
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.
Amodio V; Mauri G; Reilly NM; Sartore-Bianchi A; Siena S; Bardelli A; Germano G
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072037
[TBL] [Abstract][Full Text] [Related]
5. High numbers of PDCD1 (PD-1)-positive T cells and
Janikovits J; Müller M; Krzykalla J; Körner S; Echterdiek F; Lahrmann B; Grabe N; Schneider M; Benner A; Doeberitz MVK; Kloor M
Oncoimmunology; 2018; 7(2):e1390640. PubMed ID: 29308317
[TBL] [Abstract][Full Text] [Related]
6. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
[TBL] [Abstract][Full Text] [Related]
7. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors.
Mestrallet G; Brown M; Bozkus CC; Bhardwaj N
Front Immunol; 2023; 14():1210164. PubMed ID: 37492581
[TBL] [Abstract][Full Text] [Related]
8. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L; Hollebecque A; Yurchenko AA; de Forceville L; Danjou M; Jouniaux JM; Rosa RCA; Pouvelle C; Aoufouchi S; Vuagnat P; Smolenschi C; Colomba E; Leary A; Marabelle A; Scoazec JY; Cassard L; Nikolaev S; Chaput N; Kannouche P
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35896284
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Immune Responses in B2M-Deficient Cancers.
Torrejon DY; Galvez M; Abril-Rodriguez G; Campbell KM; Medina E; Vega-Crespo A; Kalbasi A; Comin-Anduix B; Ribas A
Cancer Immunol Res; 2023 Dec; 11(12):1642-1655. PubMed ID: 37801341
[TBL] [Abstract][Full Text] [Related]
10. Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
Barrow P; Richman SD; Wallace AJ; Handley K; Hutchins GGA; Kerr D; Magill L; Evans DG; Gray R; Quirke P; Hill J
Histopathology; 2019 Aug; 75(2):236-246. PubMed ID: 31062389
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Torrejon DY; Abril-Rodriguez G; Champhekar AS; Tsoi J; Campbell KM; Kalbasi A; Parisi G; Zaretsky JM; Garcia-Diaz A; Puig-Saus C; Cheung-Lau G; Wohlwender T; Krystofinski P; Vega-Crespo A; Lee CM; Mascaro P; Grasso CS; Berent-Maoz B; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Discov; 2020 Aug; 10(8):1140-1157. PubMed ID: 32467343
[TBL] [Abstract][Full Text] [Related]
12. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract][Full Text] [Related]
13. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.
Clendenning M; Huang A; Jayasekara H; Lorans M; Preston S; O'Callaghan N; Pope BJ; Macrae FA; Winship IM; Milne RL; Giles GG; English DR; Hopper JL; Win AK; Jenkins MA; Southey MC; Rosty C; Buchanan DD;
Fam Cancer; 2018 Jan; 17(1):91-100. PubMed ID: 28616688
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma.
Yeon Yeon S; Jung SH; Jo YS; Choi EJ; Kim MS; Chung YJ; Lee SH
Pathol Res Pract; 2019 Jan; 215(1):209-214. PubMed ID: 30503610
[TBL] [Abstract][Full Text] [Related]
16. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
Chow RD; Michaels T; Bellone S; Hartwich TMP; Bonazzoli E; Iwasaki A; Song E; Santin AD
Cancer Discov; 2023 Feb; 13(2):312-331. PubMed ID: 36301137
[TBL] [Abstract][Full Text] [Related]
17. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.
Echterdiek F; Janikovits J; Staffa L; Müller M; Lahrmann B; Frühschütz M; Hartog B; Nelius N; Benner A; Tariverdian M; von Knebel Doeberitz M; Grabe N; Kloor M
Oncoimmunology; 2016 Feb; 5(2):e1075692. PubMed ID: 27057447
[TBL] [Abstract][Full Text] [Related]
18. T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids.
Gaykema LH; van Nieuwland RY; Lievers E; Moerkerk WBJ; de Klerk JA; Dumas SJ; Kers J; Zaldumbide A; van den Berg CW; Rabelink TJ
Stem Cells Transl Med; 2024 Jan; 13(1):69-82. PubMed ID: 37843402
[TBL] [Abstract][Full Text] [Related]
19. Specific associations of fluorescent beta-2-microglobulin with cell surfaces. The affinity of different H-2 and HLA antigens for beta-2-microglobulin.
Hochman JH; Shimizu Y; DeMars R; Edidin M
J Immunol; 1988 Apr; 140(7):2322-9. PubMed ID: 2450918
[TBL] [Abstract][Full Text] [Related]
20. Major Histocompatibility Complex Class II-Restricted, CD4
Ledbetter L; Cherla R; Chambers C; Zhang Y; Mitchell WJ; Zhang G
Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31792078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
